News & Events

May 26, 2017
New MCDC Executive Committee

Small Business Category
Robert House, Ph.D. – Nanotherapeutics
Peter Latham, M.S.,PgMP – Latham BioPharm Group
Larry Zeitlin, Ph.D. – Mapp Biopharmaceutical
David Moore, DVM, Ph.D. – SciTech Services, Inc.

Large/Non-Profit Business Category
Mark Martin, Ph.D. – Janssen/Johnson & Johnson
Brian Price, Ph.D. – Battelle
Michael MacNaughton, Ph.D., P.E. – Southwest Research Institute
Veronica Hall, Ph.D. – Emergent BioSolutions

Academic Business Category
Ron Poropatich, M.D. – University of Pittsburgh

June 19-22, 2017
2017 BIO International Convention

BIO International will be held in San Diego, CA at the San Diego Convention Center. The MCDC will have a booth (#719) adjacent to the DoD Pavilion. Stop by and see us!! For information about the 2017 BIO International Convention, click here

February 21, 2017
MCDC Proposers Conference

With the recent release of MCDC-RPP-17-02 we would like to offer a Proposers Conference to review 1) the Project Award Process, 2) the RPP outline, 3) Submission Instructions, 4) Proposal Preparation (Technical and Cost), 5) Updated Communication rules, and 6) Proposal Selection. There will be an opportunity to ask questions in advance and during the conference at the end.

Time: 2:00 – 4:00 pm eastern time -- Registration is required to attend.

Date: Tuesday, February 21, 2017

Registration Link: https://attendee.gotowebinar.com/register/1490857883345225473

January 31, 2017
MCDC Proposers Conference

With the recent release of MCDC-RPP-17-01 we would like to offer a Proposers Conference to review 1) the Project Award Process, 2) the RPP outline, 3) Submission Instructions, 4) Proposal Preparation (Technical and Cost), 5) Updated Communication rules, and 6) Proposal Selection. There will be an opportunity to ask questions in advance and during the conference at the end.

Time: 2:00 – 4:00 pm eastern time --The registration page and the confirmation email will indicate that the conference time is 1:30pm – 4:30pm. This indicates the time that the webinar will be open. The actual presentation will take place from 2:00pm – 4:00pm, but the conference will be “open” at 1:30pm to allow presenters time to work through any issues. Registration is required to attend.

Date: Tuesday, January 31, 2017

Registration Link: https://attendee.gotowebinar.com/register/8495141676756753154

January 10, 2017
MCDC/JPM-MCS to Host a Webinar to Discuss Upcoming Solicitations

In response to the interest generated from the Government’s recent Intent to Announce FBO postings, ATI on behalf of the MCDC and the Joint Project Management Office for Medical Countermeasure Systems (JPM-MCS) will host a webinar for MCDC membership and other interested parties to gain additional information regarding the government’s objectives. Product Managers will provide an overview of the background and objectives for each intended project, whether each will require only a proposal or both a white paper and proposal, confidence level on funding, other information and address questions. To best manage a large virtual audience, please provide in advance any questions you may have directly to our consortium inbox at MCDC@ati.org. We will do our best to get these to the appropriate government contacts so they may be addressed during the presentation.

Time: 2:00 – 4:00 pm eastern time -- The registration page and the confirmation email will indicate that the conference time is 1:30pm – 4:30pm. This indicates the time that the webinar will be open. The actual presentation will take place from 2:00pm – 4:00pm, but the conference will be “open” at 1:30pm to allow presenters time to work through any issues.

December 1, 2016
UPDATED January 4, 2017: Government Intent to Announce Proposals for MCDC OTA

Please see the updated FBO Intent to Announce Here: FBO (W15QKN17Z081R)

November 11, 2016
MCDC Capabilities Matrix – Members Please Complete

There is desire within the Medical Countermeasure Systems (MCS) and broadly within both the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) and the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) to have an understanding of the technical capabilities of the MCDC membership base.

We have developed a brief survey which once populated by our membership will result in a comprehensive capabilities matrix that be beneficial to both the government and you and your fellow members. For the government they can identify areas of expertise and capability gaps when developing future requirements. For members you will be able to quickly assess capabilities of potential teaming partners. We ask that you take the time to complete the on-line survey as accurately as possible. The information provided will be limited to only MCDC members and the government.

Survey Link: MCDC Capabilities Matrix Survey
For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or MCDC@ati.org.

September 30, 2016
Medical CBRN Defense Consortium Announces First Award for Monoclonal Antibody Medical Countermeasure Development against Botulinum Neurotoxin

The need for a coordinated research and development program to meet DoD’s medical, pharmaceutical, and diagnostic requirements for safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear (CBRN) threats has never been greater. The Medical CBRN Defense Consortium (MCDC) was formed for the distinct purpose of collaborating to provide quick and efficient delivery of CBRN defense medical capabilities for the Joint Force under the DoD Chemical and Biological Defense Program (CBDP). The agreement between the government and the MCDC was signed April 8, 2016 and the first solicitation was released on June 22, 2016. MCDC is pleased to announce the first award was made on September 30, 2016, 100 days after release of the first solicitation.

This award is entered into under the Section 815 Prototype Other Transaction Agreement (OT) with U.S. Army Contracting Command - New Jersey (ACC-NJ), acting on behalf of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) and the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD).

The project agreement totals $39M in awarded ceiling to Nanotherapeutics for the development of Monoclonal Antibody Medical Countermeasures against Aerosolized Botulinum Toxin Serotypes A and B. The effort will address prophylactic and therapeutic indications of warfighter exposure to aerosolized Botulinum neurotoxin and supports the prototype development to a level of maturity required for filing for Investigational New Drug status with the FDA.

About Prototype Other Transaction Agreements and the Medical CBRN Defense Consortium

Other Transaction Agreements relieve some of the contractual burdens typically associated with federally-funded research, allowing the government to acquire new technology and prototypes more quickly. A major benefit of OTs is an emphasis on participation by non-traditional government contractors – small and emerging organizations that can deliver cutting-edge innovation but may not possess the contracting resources and experience typically found with performers conducting technology development for the US government.

If you are not yet a member, consider joining. Please visit the Membership page.

Questions about this press release may be directed to the MCDC consortium management firm, Advanced Technology International (ATI) at MCDC@ati.org

For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or MCDC@ati.org.

June 8, 2016
DoD and MCDC Kickoff Meeting – June 29, 2016

The Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), the Joint Science and Technology Office (JSTO) and the National Chemical & Biological Defense Consortium (NCBDC) will host the NCBDC kick-off meeting on 29 June 2016 in the National Conference Center in Leesburg, VA.

Agenda is now available, view it here. At this meeting, we will explain how interactions in the consortium will occur, DoD expectations for successful efforts, and our first requests for white papers. Break-out sessions will also be available. We hope you can attend.

The NCBDC, the JPEO-CBD, and the JSTO are partnering to support advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.

ALL INTERESTED PARTIES ARE INVITED TO ATTEND THE INITIAL OPEN SESSION. Following the open session, there will be meetings to discuss the first requests for white papers. This part of the meeting will be open to current MCDC members only. If you are not yet a member, consider joining. Please visit the Membership page.
Registration is required to attend the event; please complete the Online Registration Form Here
For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or MCDC@ati.org.

June 1, 2016
Government Intent to Announce Proposals for NCBDC OTA

Today the U.S. Army Contracting Command, Picatinny Arsenal, New Jersey, on behalf of the Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) through the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), announced via FBO (W15QKN-16-Z-05SM) its intent to announce Requests for Prototype Proposals (RPPs) under the OTA with the NCBDC. This is an intent to announce for planning purposes only and not an actual solicitation.
The Government anticipates seven (7) projects to be solicited under the OTA consisting of the following:

    Request for Prototype Proposal 1 (RPP1)
  • Development of Monoclonal Antibody Medical Countermeasures against Aerosolized Botulinum Toxin Serotypes A and B
  • Fill/Finish of Venezuelan Equine Encephilits (VEE) virus like particles (VLP) Bulk Drug Product

    Request for Prototype Proposal 2 (RPP2)
  • Development of a Dual Drug Delivery Device (D4)
  • Lyophilized Formulation and Final Product Manufacturing Process for Western/Eastern/Venezuelan Equine Encephilitis (WEVEE) Vaccine
  • VEE Monovalent VLP Phase 1 Clinical Study
  • Eastern Equine Encephilitis Vaccine (EEEV) Prototypes
  • Definitive Efficacy Studies (2) of Pyridostigmine Bromide (PB)

Please note per the notice that once the actual announcement comes out for both RPP1 and RPP2, specific information regarding the content each RPP will be available only to current NCBDC members. Membership information can be found here.

April 8, 2016
Medical Countermeasures OTA signed with NCBDC

On 8 April 2016, the OTA was finalized and the Government executed OTA W15QKN-16-9-1 to conduct collaborative, prototype research projects with NCBDC members with a cumulative value up to $10B over the next 20 years.

January 11, 2016
Intent to Award – Medical Countermeasures OTA

Congratulations Stakeholders! Today the U.S. Army Contracting Command, Picatinny Arsenal, New Jersey, on behalf of the Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) through the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), announced its intent to enter into a Section 815 Other Transaction (OT) Agreement with the National Chemical and Biological Defense Consortium (NCBDC) for a period of twenty (20) years.

The Special Notice cites: “Only one such Consortium, the National Chemical and Biological Defense Consortium, encompasses the expertise, knowledge, technologies, and innovation to meet the program objectives and goals of the coordinated research and development program designed to support the Department of Defense's medical, pharmaceutical, and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. The consortium is comprised of a well-balanced and uniquely qualified mixture of traditional and non-traditional contractors, small and large business, for-profit and not-for-profit entities, and academic organizations.”

The full announcement is available on FedBizOpps under solicitation number: W15QKN-16Z-03KL

The NCBDC is an open consortium with a low barrier for membership. Any interested company, academic institution, or contractor can become a member and join the consortium to widen knowledge and technical expertise to continue to advance in technologies and meet Government needs. For more information, interested parties can visit the consortium website at www.ncbdconsortium.org.